HRTX Heron Therapeutics Inc

$HRTX Just a quick update - no news on the appeal case at all. Bryson has not ruled at all on the emergency stay, so at this point, we can assume that he does not intend to rule at all, and is proactively indicating that Heron should escalate the emergency stay to the appellate court if they want. No news from Azurity about their appellee briefing - that is due on October 25th. It is typical that appellee's will ask for and be granted a 30 day extension, so maybe Azurity plans on doing that. All this no-news itself is the news - there should be no impact to Cinvanti sales in Q3 and Q4 - so, fiscal 2026 - unless cancer patients are somehow deciding not to contract cancer until the appeal is settled. Which means that, despite having formally withdrawn their full year guideline, Heron should be able to meet the $173M target. Let's really hope Q3 was on target - the modest but reliable steady growth in Zyn and Aponvie, and some recovery on Cinvanti.

$HRTX I think the sequence of events at HRTX tells us a lot about management’s intentions. After the CINVANTI patent ruling, management stopped expanding its sales force, cut spending, and announced strategic alternatives. To me, this suggests they may have decided that continuing their original growth strategy was no longer the best option. If management believed expanding the sales force would generate enough revenue to achieve profitability, why stop? The quick settlement with Long Grove also suggests they may be cleaning up legal uncertainties ahead of a potential transaction. Taken together, these actions look more like preparation for a strategic transaction than ordinary cost-cutting. That’s why I believe the Q3 earnings call could provide important clues. Quarterly revenue still matters, but the bigger catalyst may be the outcome of the strategic review rather than short-term sales growth.

$HRTX Looking at Short numbers, 46M shares short is insane, unbelievable to even fathom. Taking a closer look the number was sitting at 32M 1 year ago. We are here as a result. Tacto is 100% correct that these numbers do set up for a big potential short squeeze but as we know a rocket needs lots of fuel for takeoff. To date CEO has not provided that. We also had big revenue misses last 2 quarters. Very encouraging last week to see volume increase while stock price shot up. If CEO has anything up his sleeve oh boy now would be the time to release the Kracken. Have to say this week will be very interesting, would like to see this trend continue as that would be a sure sign something is on the horizon, We as a group are long overdue for some positive news.

$HRTX Another reason I see a significant opportunity here is the following. Three relevant franchises, right? Potentially, a few more exclusive acute-care franchises in Q3, would generate additional revenue going forward. Now, let's talk about a buyout. Even under bearish scenario, Cinvanti's forward-looking gains alone are worth$189M franchise, equivalent to $1 per share(If you want to be extremely bearish, that franchise covers the company's ~$100M in net debt.) Under a bullish scenario, with no generics for several years, we're talking about$300M worth franchise. Then you have Zynrelef and Aponvie. Let's say around $300M for the pair. So, whether a bearish or bullish scenario, this company should already be trading above $1. But sometimes stocks go through periods of hitting all-time lows. You just have to believe you're wise enough to analyze the opportunity correctly. I do&did well with Xeris&Esperion, but until you make it with Heron, you can't call yourself a stonks guru;)

$HRTX Recovering a bit since the end of Sept. Looks like the new deal has been well received. I've not seen that the generic Cinvanti launched anyway, and every quarter that it doesn't is another quarter for Zyn/Apon to grow. Holding here, but this has been a dog of a stock.

$HRTX Kind of a mini breakout from the highs of the last few months today closing at .4061 on decent volume. More inpressive is the substantial daily increase in volume from 9/29/26 to date while the price is working higher and higer. This looks and smells a bit different!

$HRTX With Zynrelef, Aponvie, Cinvanti, and potentially several more exclusive acute care franchises under the same marketing line since Q3, the storyline here is becoming really interesting. Anyway, there is no reason for the stock to be below $1 given the company's current revenue and its position on the verge of profitability. I've understood the Cinvanti scare, but even in a reasonable bearish scenario where one generic enters the market, Zynrelef, Aponvie, and a few more acute care franchises should offset a 10-20% decline. So, even in a reasonable bearish scenario, trading below $1 makes little sense given what the company is generating, with growing assets already generating nearly $200M in revenue and profitability not far away. Now, let's talk about mid-case and bull-case scenarios, and we're counting in dollars. However you look at it, this is not a failed clinical-stage bio, but a company with strong, growing commercial assets and now, potentially, several more.

$HRTX Heron will participate in the Eastern Orthopaedic Association Congress on October 14-17 in Miami, FL. It will also participate in the American Society of Anesthesiologists Congress on October 16-20 in San Diego, CA.

$HRTX Of the 4.7M overall volume today, 1.3M came out of the shorting pool (5.4 - 4.1 = 1.3), and they sold the other 3.4M to themselves in phony off-exchange transactions That's why daily short volume was just 37%, and so-called 'dark pool' volume was 3,385,296 It costs them nothing to report fake off-exchange transactions, and they avoid going that much deeper into the short hole, which is already nearly 50M deep, and there's no chance whatsoever that they can ever escape intact from that. Meanwhile, we sit tight. Tick tock, tick tock.... . . .

$HRTX The market is waiting for news, and they should announce the earnings date this week. Last year, Q3 earnings date was on November 4, so let’s see if they follow a similar timeline or push it to the following week. More importantly, I hope management presents a clear plan for the future—whether that means selling the company or continuing operations with a solid strategy. Shareholders deserve clarity about where the company is headed.

$HRTX Short interest for the end of September was just posted, and it looks like a big f'n Squeeze is on the near horizon. Not only did the bad guys not make any progress with finding genuine shares to cover their mammoth short heap, they actually were forced to go an additional 2.6M deeper in the hole just to delay their demise. Oh boy, it's gonna be a hell of a show! 🎟️🥤🍿 📽 ☄️💥💥 . .

$HRTX is signing a 10-year multi-product licensing agreement. That suggests management isn’t simply trying to shrink HRTX. It is also trying to rebuild/expand the commercial portfolio. IMHO, strategically positive!

$HRTX What’s bothering me is the heavy volume and price decline over the last two sessions. Was it institutional selling or short pressure? I know the broader market has been red lately, but we’re approaching one of the most important earnings reports, which should give us clues about the company’s future plans, regardless of the actual growth numbers. Last quarter’s biggest disappointment was Craig Collard’s failure to communicate clearly and reassure shareholders during an already difficult period, especially after promising growth in the previous quarter. This time, investors need clarity, accountability, and a credible path forward. I hope things improve and we finally start seeing some light at the end of the tunnel.

$HRTX Although none of us knows exactly what’s happening behind closed doors, companies typically consider bankruptcy when other options become limited. Heron still has products with growth potential if it improves its sales execution. It’s also negotiating with lenders and reportedly exploring partnerships with companies it has had disputes with. CINVANTI faces challenges following the patent loss, but until we see the impact of generic competition on sales, the full effect remains unclear. In my opinion, Heron could still have a path to recovery if management secures the right partnership, restructures its debt successfully, or sells the company.

$HRTX If they go as is —> equity eventually go to zero If they get acquired —> we get about $1.5 If they merge with another bio that has cost saving synergies —> tbd , but about $1 to $2

$HRTX Sit tight! Like I said before, to better understand the game here, study the recent PDSB move from $0.20 to today's $1.60, which is still very much in progress, and you will see how the stock operator shakes out the more feeble-minded types with some very deep and sharp dips along the way. HRTX is gonna go a hell of a lot higher than PDSB ever will, given the dynamics involved, but the stock operators' shenanigans are the same, so don't be the dimwit who gets dropped off in the early stages of this trip to Mars or beyond . .

$HRTX pulled it down today but jumped back up after hours. We will see a lot of this action if it has any uptrend over the next 6 months. As you all know it needs to get above $5 to ever be bought by most investors. Don't know if we will ever see that again but good luck to all the longs that have been around for years. Who knows maybe Collard can pull something out if the hat and surprise everyone. Not going to hold my breath but sure would be nice.

$HRTX 3 - Products were not named. Long Grove’s public book is hospital injectables (premix norepi, vasopressin, fluorescein, dalbavancin, etc.). Those fit Heron’s acute-care bag better than they fit a secret CINVANTI work-around. A multi-product deal also matches Capstone’s model of warehousing several programs and handing commercialization to someone with a field force. So the simple reason: Heron needs revenue-bearing hospital products fast and cheap; Long Grove needs a U.S. commercial partner; Water Street/Capstone will take milestones and royalties instead of building a 100-rep sales org.

$HRTX Settlement with Long Grove could also be cleaning the books before a merger or sale. That value is now known to a buyer

$HRTX i have been here for way to long and a short squeeze has been predicted since we dropped below $10 at the end of 2021. Not being negative but 5 years of saying a short squeeze is around the corner is crazy until we have not just good sales but fabulous sales which is not happening yet. I am to the point that I would be some what happy to see $5, so we could get more long term holders instaed of day traders.